QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-axogen-raises-price-target-to-20

JMP Securities analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target fro...

 axogen-expects-fy24-revenue-of-182m-186m-prior-177m-181m-vs-1789m-est

2024 Financial Guidance We are increasing our annual revenue guidance to the range of $182 million to $186 million. We are als...

 axogen-tapped-michael-dale-as-ceo-and-director-effective-august-9-taking-over-from-karen-zaderej

Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...

 raymond-james-initiates-coverage-on-axogen-with-outperform-rating-announces-price-target-of-13

Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price...

 axogen-launches-new-product-to-aid-nerve-healing-avive-soft-tissue-matrix

Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve inju...

 canaccord-genuity-reiterates-buy-on-axogen-maintains-15-price-target

Canaccord Genuity analyst Caitlin Cronin reiterates Axogen (NASDAQ:AXGN) with a Buy and maintains $15 price target.

 axogen-initiates-rolling-submission-process-with-fda-for-biologics-license-application-for-licensure-of-avance-nerve-graft

The company anticipates the BLA filing to be completed in the third quarter of 2024 and believe the procedural timelines for re...

 axogen-q1-2024-adj-eps-006-beats-007-estimate-sales-41378m-miss-41964m-estimate

Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14....

 why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

 axogen-q4-eps-006-beats-010-estimate-sales-4290m-beat-4165m-estimate

Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 40 ...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 axogen-earnings-preview
Axogen Earnings Preview
03/04/2024 15:01:29

 cantor-fitzgerald-reiterates-overweight-on-axogen-maintains-12-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates Axogen (NASDAQ:AXGN) with a Overweight and maintains $12 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION